Estrogen and androgen receptors: Regulators of fuel homeostasis and emerging targets for diabetes and obesity

Trends in Endocrinology and Metabolism

Volumn 22, Issue 1, 2011, Pages 24-33

  Mauvais Jarvis, Franck ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; ANDROGEN RECEPTOR; APOPTOSIS SIGNAL REGULATING KINASE 1; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FATTY ACID; GLUCOSE TRANSPORTER 4; GUANINE NUCLEOTIDE BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STREPTOZOCIN; TESTOSTERONE; TRANSCRIPTION FACTOR AP 1;

ADIPOSE TISSUE; AGE; CALORIC INTAKE; CELL SURVIVAL; ENERGY EXPENDITURE; ESTROGEN DEFICIENCY; ESTROGEN RESPONSIVE ELEMENT; HOMEOSTASIS; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; LIPOGENESIS; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; RODENT; THALAMUS VENTRAL NUCLEUS; ZUCKER DIABETIC FATTY RAT;

ANIMALS; DIABETES MELLITUS; FEMALE; HOMEOSTASIS; HUMANS; MALE; OBESITY; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN;

EID: 78650521925     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2010.10.002     Document Type: Review

References (97)

1. Wild S., et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
2. Alberti K.G., et al. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet. Med. 2006, 23:469-480.
3. Hill J.W., et al. Hypothalamic pathways linking energy balance and reproduction. Am. J. Physiol. Endocrinol. Metab. 2008, 294:E827-832.
4. Shi H., et al. Sexual differences in the control of energy homeostasis. Front Neuroendocrinol. 2009, 30:396-404.
5. Carr MC The emergence of the metabolic syndrome with menopause. J. Clin. Endocrinol. Metab. 2003, 88:2404-2411.
6. Zitzmann M Testosterone deficiency, insulin resistance and the metabolic syndrome. Nat. Rev. Endocrinol. 2009, 5:673-681.
7. Simpson E.R. Sources of estrogen and their importance. J. Steroid. Biochem. Mol. Biol. 2003, 86:225-230.
8. Weihua Z., et al. An endocrine pathway in the prostate, ERbeta, AR, 5alpha-androstane-3beta,17beta-diol, and CYP7B1, regulates prostate growth. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:13589-13594.
9. Nilsson S., et al. Mechanisms of estrogen action. Physiol. Rev. 2001, 81:1535-1565.
10. Levin E.R. Plasma membrane estrogen receptors. Trends Endocrinol. Metab. 2009, 20:477-482.
11. Liu S., Mauvais-Jarvis F. Minireview: Estrogenic protection of beta-cell failure in metabolic diseases. Endocrinology 2010, 151:859-864.
12. Jones M.E., et al. Aromatase-deficient (ArKO) mice have a phenotype of increased adiposity. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:12735-12740.
13. Heine P.A., et al. Increased adipose tissue in male and female estrogen receptor-alpha knockout mice. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:12729-12734.
14. Ribas V., et al. Impaired Oxidative metabolism and inflammation are associated with insulin resistance in ER{alpha} deficient mice. Am. J. Physiol. Endocrinol. Metab. 2009, 298:E304-E319.
15. Clegg D.J., et al. Gonadal hormones determine sensitivity to central leptin and insulin. Diabetes 2006, 55:978-987.
16. Gao Q., et al. Anorectic estrogen mimics leptin's effect on the rewiring of melanocortin cells and Stat3 signaling in obese animals. Nat. Med. 2007, 13:89-94.
17. Geary N., et al. Deficits in E2-dependent control of feeding, weight gain, and cholecystokinin satiation in ER-alpha null mice. Endocrinology 2001, 142:4751-4757.
18. Liang Y.Q., et al. Estrogen receptor beta is involved in the anorectic action of estrogen. Int. J. Obes. Relat. Metab. Disord. 2002, 26:1103-1109.
19. Olofsson L.E., et al. Functional requirement of AgRP and NPY neurons in ovarian cycle-dependent regulation of food intake. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:15932-15937.
20. Thammacharoen S., et al. Hindbrain administration of estradiol inhibits feeding and activates estrogen receptor-alpha-expressing cells in the nucleus tractus solitarius of ovariectomized rats. Endocrinology 2008, 149:1609-1617.
21. Musatov S., et al. Silencing of estrogen receptor alpha in the ventromedial nucleus of hypothalamus leads to metabolic syndrome. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:2501-2506.
22. Yepuru M., et al. Estrogen receptor-{beta} selective ligands alleviate high-fat diet- and ovariectomy-induced obesity in mice. J. Biol. Chem. 2010, 285:31292-31303.
23. Haas E., et al. Regulatory role of G protein-coupled estrogen receptor for vascular function and obesity. Circ. Res. 2009, 104:288-291.
24. Langer G., et al. A critical review of fundamental controversies in the field of GPR30 research. Steroids 2010, 75:603-610.
25. Dhillon, S.S. and Belsham D.D. (2010) Estrogen inhibits NPY secretion through membrane-associated estrogen receptor (ER)-alpha in clonal, immortalized hypothalamic neurons. Int. J. Obes. (Lond.). Jun 15 [Epub ahead of print].
26. Qiu J., et al. A G-protein-coupled estrogen receptor is involved in hypothalamic control of energy homeostasis. J. Neurosci. 2006, 26:5649-5655.
27. Roepke T.A., et al. Contribution of a membrane estrogen receptor to the estrogenic regulation of body temperature and energy homeostasis. Endocrinology 2010, 15:4926-4937.
28. D'Eon T.M., et al. Estrogen regulation of adiposity and fuel partitioning. Evidence of genomic and non-genomic regulation of lipogenic and oxidative pathways. J. Biol. Chem. 2005, 280:35983-35991.
29. Bryzgalova G., et al. Mechanisms of antidiabetogenic and body weight-lowering effects of estrogen in high-fat diet-fed mice. Am. J. Physiol. Endocrinol. Metab. 2008, 295:E904-912.
30. Gao H., et al. Long-term administration of estradiol decreases expression of hepatic lipogenic genes and improves insulin sensitivity in ob/ob mice: a possible mechanism is through direct regulation of signal transducer and activator of transcription 3. Mol. Endocrinol. 2006, 20:1287-1299.
31. Lundholm L., et al. The estrogen receptor {alpha}-selective agonist propyl pyrazole triol improves glucose tolerance in ob/ob mice; potential molecular mechanisms. J. Endocrinol. 2008, 199:275-286.
32. Cooke P.S., Naaz A. Role of estrogens in adipocyte development and function. Exp. Biol. Med. (Maywood) 2004, 229:1127-1135.
33. Foryst-Ludwig A., et al. Metabolic actions of estrogen receptor beta (ERbeta) are mediated by a negative cross-talk with PPARgamma. PLoS Genet. 2008, 4:e1000108.
34. Morishima A., et al. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J. Clin. Endocrinol. Metab. 1995, 80:3689-3698.
35. Smith E.P., et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N. Engl. J. Med. 1994, 331:1056-1061.
36. Bryzgalova G., et al. Evidence that oestrogen receptor-alpha plays an important role in the regulation of glucose homeostasis in mice: insulin sensitivity in the liver. Diabetologia 2006, 49:588-597.
37. Barros R.P., et al. Muscle GLUT4 regulation by estrogen receptors ERbeta and ERalpha. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:1605-1608.
38. Riant E., et al. Estrogens protect against high-fat diet-induced insulin resistance and glucose intolerance in mice. Endocrinology 2009, 150:2109-2117.
39. Naaz A., et al. Effect of ovariectomy on adipose tissue of mice in the absence of estrogen receptor alpha (ERalpha): a potential role for estrogen receptor beta (ERbeta). Horm. Metab. Res. 2002, 34:758-763.
40. Barros R.P., et al. Participation of ERalpha and ERbeta in glucose homeostasis in skeletal muscle and white adipose tissue. Am. J. Physiol. Endocrinol. Metab. 2009, 297:E124-133.
41. Barros R.P., et al. Estrogen receptors: new players in diabetes mellitus. Trends Mol. Med. 2006, 12:425-431.
42. Nadal A., et al. The pancreatic beta-cell as a target of estrogens and xenoestrogens: Implications for blood glucose homeostasis and diabetes. Mol. Cell Endocrinol. 2009, 304:63-68.
43. Ding E.L., et al. Plasma sex steroid hormones and risk of developing type 2 diabetes in women: a prospective study. Diabetologia 2007, 50:2076-2084.
44. Kalyani R.R., et al. The association of endogenous sex hormones, adiposity, and insulin resistance with incident diabetes in postmenopausal women. J. Clin. Endocrinol. Metab. 2009, 94:4127-4135.
45. Verchere C.B., et al. Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:3492-3496.
46. Kahn S.E., et al. Oophorectomy promotes islet amyloid formation in a transgenic mouse model of Type II diabetes. Diabetologia 2000, 43:1309-1312.
47. Geisler J.G., et al. Estrogen can prevent or reverse obesity and diabetes in mice expressing human islet amyloid polypeptide. Diabetes 2002, 51:2158-2169.
48. Le May C., et al. Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:9232-9237.
49. Alonso-Magdalena P., et al. Pancreatic insulin content regulation by the estrogen receptor ER alpha. PLoS ONE 2008, 3:e2069.
50. Liu S., et al. Importance of extranuclear estrogen receptor-alpha and membrane G protein-coupled estrogen receptor in pancreatic islet survival. Diabetes 2009, 58:2292-2302.
51. Liu S., Mauvais-Jarvis F. Rapid, nongenomic estrogen actions protect pancreatic islet survival. Islets 2009, 1:273-275.
52. Martensson U.E., et al. Deletion of the G protein-coupled receptor 30 impairs glucose tolerance, reduces bone growth, increases blood pressure, and eliminates estradiol-stimulated insulin release in female mice. Endocrinology 2009, 150:687-698.
53. Balhuizen A., et al. Activation of G protein-coupled receptor 30 modulates hormone secretion and counteracts cytokine-induced apoptosis in pancreatic islets of female mice. Mol. Cell Endocrinol. 2010, 320:16-24.
54. Kang L., et al. Involvement of estrogen receptor variant ER-alpha36, not GPR30, in nongenomic estrogen signaling. Mol. Endocrinol. 2010, 24:709-721.
55. Soriano S., et al. Rapid regulation of K(ATP) channel activity by 17{beta}-estradiol in pancreatic {beta}-cells involves the estrogen receptor {beta} and the atrial natriuretic peptide receptor. Mol. Endocrinol. 2009, 23:1973-1982.
56. Tokuyama Y., et al. Evolution of beta-cell dysfunction in the male Zucker diabetic fatty rat. Diabetes 1995, 44:1447-1457.
57. Lee Y., et al. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:10878-10882.
58. Tiano J, et al., (2010) The extranuclear estrogen receptora improves pancreatic islet lipid homeostasis. The Endocrine Society's 92nd Annual Meeting San Diego, CA June 19-22, 2010 OR18-6.
59. Wong W.P., et al. Extranuclear estrogen receptor-{alpha} stimulates NeuroD1 binding to the insulin promoter and favors insulin synthesis. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:13057-13062.
60. Beato M Gene regulation by steroid hormones. Cell 1989, 56:335-344.
61. Schoenmakers E., et al. Differences in DNA binding characteristics of the androgen and glucocorticoid receptors can determine hormone-specific responses. J. Biol. Chem. 2000, 275:12290-12297.
62. Foradori C.D., et al. Non-genomic actions of androgens. Front Neuroendocrinol. 2008, 29:169-181.
63. Khaw K.T., Barrett-Connor E. Lower endogenous androgens predict central adiposity in men. Ann. Epidemiol. 1992, 2:675-682.
64. Zitzmann M., et al. Association of specific symptoms and metabolic risks with serum testosterone in older men. J. Clin. Endocrinol. Metab. 2006, 91:4335-4343.
65. Bojesen A., et al. The metabolic syndrome is frequent in Klinefelter's syndrome and is associated with abdominal obesity and hypogonadism. Diabetes Care 2006, 29:1591-1598.
66. Basaria S., et al. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 2006, 106:581-588.
67. Pitteloud N., et al. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 2005, 28:1636-1642.
68. Moverare-Skrtic S., et al. Dihydrotestosterone treatment results in obesity and altered lipid metabolism in orchidectomized mice. Obesity (Silver Spring) 2006, 14:662-672.
69. Zitzmann M., et al. The CAG repeat polymorphism in the androgen receptor gene modulates body fat mass and serum concentrations of leptin and insulin in men. Diabetologia 2003, 46:31-39.
70. Fan W., et al. Androgen receptor null male mice develop late-onset obesity caused by decreased energy expenditure and lipolytic activity but show normal insulin sensitivity with high adiponectin secretion. Diabetes 2005, 54:1000-1008.
71. Lin H.Y., et al. Insulin and leptin resistance with hyperleptinemia in mice lacking androgen receptor. Diabetes 2005, 54:1717-1725.
72. Lanfranco F., et al. Serum adiponectin levels in hypogonadal males: influence of testosterone replacement therapy. Clin. Endocrinol. (Oxf.) 2004, 60:500-507.
73. Nishizawa H., et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 2002, 51:2734-2741.
74. Singh R., et al. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology 2003, 144:5081-5088.
75. Singh R., et al. Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. Endocrinology 2006, 147:141-154.
76. Gentile M.A., et al. Androgen-mediated improvement of body composition and muscle function involves a novel early transcriptional program including IGF1, mechano growth factor, and induction of {beta}-catenin. J. Mol. Endocrinol. 2010, 44:55-73.
77. Fernando S.M., et al. Myocyte androgen receptors increase metabolic rate and improve body composition by reducing fat mass. Endocrinology 2010, 151:3125-3132.
78. Yu I.C., et al. Hyperleptinemia without obesity in male mice lacking androgen receptor in adipose tissue. Endocrinology 2008, 149:2361-2368.
79. Mootha V.K., et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 2003, 34:267-273.
80. Fan W., et al. Functional potentiation of leptin-signal transducer and activator of transcription 3 signaling by the androgen receptor. Endocrinology 2008, 149:6028-6036.
81. Maclaren N.K., et al. Androgen sensitization of streptozotocin-induced diabetes in mice. Diabetes 1980, 29:710-716.
82. Paik S.G., et al. Induction of insulin-dependent diabetes by streptozotocin. Inhibition by estrogens and potentiation by androgens. Diabetes 1982, 31:724-729.
83. Morimoto S., et al. Protective effect of testosterone on early apoptotic damage induced by streptozotocin in rat pancreas. J. Endocrinol. 2005, 187:217-224.
84. Palomar-Morales M., et al. The protective effect of testosterone on streptozotocin-induced apoptosis in beta cells is sex specific. Pancreas 2010, 39:193-200.
85. Sato T., et al. Late onset of obesity in male androgen receptor-deficient (AR KO) mice. Biochem. Biophys. Res. Commun. 2003, 300:167-171.
86. Dati E., et al. Body composition and metabolic profile in women with complete androgen insensitivity syndrome. Sex Dev. 2009, 3:188-193.
87. Achard C., Thiers J. Le virilisme pilaire et son association a l'insuffisance glycolytique (diabete des femmes a barbe). Bull. Acad. Natl. Med. Paris 1921, 86:51-55.
88. Coviello A.D., et al. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J. Clin. Endocrinol. Metab. 2006, 91:492-497.
89. Diamond M.P., et al. Effects of methyltestosterone on insulin secretion and sensitivity in women. J. Clin. Endocrinol. Metab. 1998, 83:4420-4425.
90. Holmang A., et al. Effects of testosterone on muscle insulin sensitivity and morphology in female rats. Am. J. Physiol. 1990, 259:E555-560.
91. O'Meara N.M., et al. Defects in beta-cell function in functional ovarian hyperandrogenism. J. Clin. Endocrinol. Metab. 1993, 76:1241-1247.
92. Holte J., et al. Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance. J. Clin. Endocrinol. Metab. 1994, 78:1052-1058.
93. Goodarzi M.O., et al. beta-Cell function: a key pathological determinant in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2005, 90:310-315.
94. Liu S., et al. Androgen excess produces systemic oxidative stress and predisposes to beta-cell failure in female mice. PLoS One 2010, 5:e11302.
95. Gonzalez F., et al. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2006, 91:336-340.
96. Navarro, G. et al. (2010) Androgen excess in females predisposes to insulin deficiency via AR in beta-cells. 92nd Annual Meeting of the Endocrine Society, San Diego, CA, 19-22 June 2010, PI-468.
97. Corbould A Effects of androgens on insulin action in women: is androgen excess a component of female metabolic syndrome?. Diabetes Metab. Res. Rev. 2008, 24:520-532.